
    
      PRIMARY OBJECTIVES:

      I. To determine the maximal tolerated dose (MTD) for the combination of temsirolimus and
      vinorelbine in advanced solid tumors.

      II. To obtain preliminary information regarding the activity of this combination.

      SECONDARY OBJECTIVES:

      I. To evaluate the safety and tolerability of this combination.

      OUTLINE:

      Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22 and vinorelbine
      ditartrate IV over 5-10 minutes on days 1 and 15. Courses repeat every 28 days in the absence
      of disease progression or unacceptable toxicity.
    
  